De Lin Yu

US Patent:

6495130, Dec 17, 2002

Filed:

Dec 29, 1999

Appl. No.:

09/474699

Inventors:

Daniel R. Henderson - Palo Alto CA
De Chao Yu - Foster City CA

Assignee:

Calydon, Inc. - Sunnyvale CA

International Classification:

A61K35300

US Classification:

424 932, 424 931, 424 936, 4353201, 435325, 435455, 514 44

Abstract:

The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells is desirable. The invention further provides host cells comprising the vectors. The invention further provides methods of using the adenoviral vectors.

US Patent:

6900049, May 31, 2005

Filed:

Sep 9, 1999

Appl. No.:

09/392822

Inventors:

De Chao Yu - Foster City CA, US
Daniel R. Henderson - Palo Alto CA, US

Assignee:

Cell Genesys, Inc. - San Francisco CA

International Classification:

A01N063/00
A61K039/00
C12N015/00
C12N005/00
C12P021/06

US Classification:

4353201, 435 691, 435325, 424 931, 4241911, 536231

Abstract:

The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.

US Patent:

6916918, Jul 12, 2005

Filed:

Jun 5, 2001

Appl. No.:

09/875228

Inventors:

De Chao Yu - Foster City CA, US
Daniel R. Henderson - Palo Alto CA, US
Eric R. Schuur - Palo Alto CA, US

Assignee:

Cell Genesys, Inc. - South San Francisco CA

International Classification:

C07H021/04
C12N015/74

US Classification:

536 241, 4353201

Abstract:

Enhancers which preferentially increase the transcription of cis-linked coding sequences in prostate cells are provided. Methods of using DNA constructs comprising the enhancers to control transcription of heterologous polynucleotides are also provided. Delivery vehicles comprising the enhancers and methods of using the vehicles are also provided. Adenovirus vectors in which one or more genes are under transcriptional control of the enhancers of the invention are also provided. Further provided are methods of using the adenovirus vectors of the invention to confer selective cytotoxicity in mammalian cells.

US Patent:

7048920, May 23, 2006

Filed:

Jan 15, 2002

Appl. No.:

10/053886

Inventors:

De Chao Yu - Foster City CA, US
Yuanhao Li - Palo Alto CA, US

Assignee:

Cell Genesys, Inc. - South San Francisco CA

International Classification:

A01N 63/00
A61K 48/00

US Classification:

424 932, 435455, 435456, 4353201

Abstract:

The invention provides melanoma cell specific adenovirus vectors, which preferentially replicate in melanoma cells.

US Patent:

7371570, May 13, 2008

Filed:

Oct 30, 2003

Appl. No.:

10/698160

Inventors:

De Chao Yu - Foster City CA, US
Nagarajan Ramesh - Santa Clara CA, US

Assignee:

Cell Genesys, Inc. - South Francisco CA

International Classification:

C12N 15/861
C12N 5/10
A61K 48/00

US Classification:

4353201, 435325, 536 231, 536 241

Abstract:

Replication-competent adenoviral vectors comprising an EBV-specific transcriptional regulatory element (TRE) operably linked to a gene required for adenovirus replication are provided. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication can be restricted to particular target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.

US Patent:

RE42373, May 17, 2011

Filed:

Jul 29, 2008

Appl. No.:

12/221052

Inventors:

De Chao Yu - Palo Alto CA, US
Daniel R. Henderson - Del Mar CA, US

International Classification:

A01N 63/00
A61K 39/00
C12N 15/00

US Classification:

4353201, 435 691, 435325, 424 931, 4241911, 536 231

Abstract:

The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.

US Patent:

20030118555, Jun 26, 2003

Filed:

Aug 21, 2002

Appl. No.:

10/226820

Inventors:

Daniel Henderson - Palo Alto CA, US
De Yu - Foster City CA, US

International Classification:

A61K048/00
C12N007/00
C12N015/861

US Classification:

424/093200, 435/456000, 435/320100, 435/235100

Abstract:

The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells is desirable. The invention further provides host cells comprising the vectors. The invention further provides methods of using the adenoviral vectors.

US Patent:

20030180936, Sep 25, 2003

Filed:

Sep 24, 2002

Appl. No.:

10/254156

Inventors:

Bahram Memarzadeh - San Carlos CA, US
Joseph Wypych - Tracy CA, US
De Yu - Foster City CA, US

International Classification:

C12N007/02
C12Q001/70
C12N013/00
C12N007/00
C12N007/01

US Classification:

435/239000, 435/005000, 435/235100, 435/173900

Abstract:

A process is provided for the production of substantially pure replication competent adenovirus, together with improved formulations for maintenance of infectivity following storage. In the process, virus infected cells are lysed with detergent. An initial purification step utilizes a pass through a high throughput ion exchange filter. The eluant is treated with nuclease, then refiltered on a high throughput ion exchange filter. The virus formulation provides for enhanced stability of liquid viral preparations at 5 C.